Background and aim: Limited-stage combined small cell esophageal carcinoma (LS-C-SCEC) is a rare, poorly understood, underdiagnosed disease, with components of both small cell esophageal cancer and non-small cell esophageal cancer. We investigated the optimal treatment strategy and prognostic factors in patients with LS-C-SCEC. Patients and methods: LS-C-SCEC patients included in the analysis (from our hospital and the literature) were treated between January 1966 and December 2013. Patient treatment strategies included surgery (S), chemotherapy (CT), and radiation therapy (RT). The primary end point was overall survival (OS); the secondary end points included tumor complete response rates, patterns of failure, and toxicity. Kaplan-Meier curves were compared with the log-rank test. Univariate and multivariate analyses were used to determine prognosticators for OS. 
Introduction
The esophagus is the main site of extrapulmonary small cell carcinoma, and primary small cell esophageal carcinoma (SCEC) represents 1.0% to 2.8% of all esophageal cancers. 1, 2 The incidence of SCEC is highest in Southeast Asian countries, including Japan, Korea, and the People's Republic of China. 3, 4 SCEC is similar to small cell lung cancer (SCLC) in that both have a high frequency of regional and distant spread at time of diagnosis and a poor overall prognosis. 5, 6 The term "combined SCEC" (C-SCEC) is defined by World Health Organization (WHO) as SCEC with an additional component of non-small cell carcinoma, including squamous cell carcinoma, adenocarcinoma, or other carcinoma. Limited-stage (LS) C-SCEC (LS-C-SCEC) is currently considered a subset of SCEC, although biologic evidence to support this classification scheme is lacking. An accurate understanding of LS-C-SCEC is of great practical importance; its optimal treatment strategy may 
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Wang et al be different than that of pure SCEC, 4,7-9 neuroendocrine esophageal carcinoma, 10 or non-SCEC, 11 akin to pure SCLC and combined SCLC (C-SCLC). 12, 13 Evidence behind the optimal therapeutic approaches to LS-C-SCEC is limited because of (1) the infrequency of the disease; (2) various treatment strategies (including surgery [S] , chemotherapy [CT] , radiotherapy [RT] , and combinations of these treatments) have been reported to have similar outcomes; 4 and (3) the prognosis for pure SCEC and C-SCEC is reportedly similar. 4 Our previous study demonstrated that patients with pure LS-SCEC treated with RT+CT had an improved survival compared with those treated with S+CT. 8 We believe LS-C-SCEC is a unique disease, and its optimal management may be different than that of LS-SCEC. Therefore, we performed a retrospective study to evaluate the clinical features, optimal treatment strategy, and prognostic factors in patients with LS-C-SCEC.
Patients and methods study design and patient eligibility
Eligible patients with LS-C-SCEC were recruited from our hospital and the literature.
2,5,9,14-31 The inclusion criteria were: (1) a pathological diagnosis of primary LS-C-SCEC; (2) treatment, including S, RT, CT, or a combination of these; and (3) a report of overall survival (OS) time. The exclusion criteria for patients were as follows: (1) a diagnosis of pure esophageal carcinomas (eg, squamous cell carcinoma, adenocarcinoma, or small cell carcinoma); (2) a diagnosis of extensive stage C-SCEC; (3) uncontrolled comorbid conditions (metabolic or psychiatric); and (4) an unreported OS time. The study protocol was in accordance with the ethical guidelines of the 1995 Declaration of Helsinki and was approved by independent ethics committees at Tianjin Medical University Cancer Institute and Hospital.
literature search strategy and data extraction
We searched MEDLINE for patients treated for SCEC between January 1966 and December 2013. A preliminary search was designed to find all articles including the terms "small cell carcinoma" or "oat cell carcinoma" combined with "esophagus" or "esophageal." Three reviewers independently selected the patients and performed the data extraction, from these articles and their references. Discrepancies regarding stated information in articles were resolved by discussion among reviewers. All principal investigators who initially included these patients were contacted using the corresponding e-mail addresses listed in the respective studies. The message sent to the authors both acknowledged their original work and asked for permission to include their patients in the current study. Of the authors without functioning addresses, none objected to having his/ her patients included in the current study. Further, principal investigators were asked to supplement information that was missing from the original publication.
Treatment schedule
S was defined as radical resection of the primary tumor and/or local lymphadenectomy. RT was administered with conventional fields (two anterior-posterior opposed fields and two anterior-posterior [AP-PA] oblique opposed fields), three-dimensional (3D) conformal radiotherapy (3D-CRT), or intensity-modulated radiotherapy (IMRT). Data gathered about CT included agent(s) used and number of CT cycles. 
Outcome measurements and end points

Results
Patient characteristics
A total of 72 patients were included in the analysis: 24 patients (33%) from our hospital and 48 patients (67%) 
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Multimodality therapy is recommended for ls-c-scec from 21 publications. 2, 5, 9, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The baseline characteristics of all patients are shown in Table 1 . The characteristics of patients from our institution are summarized in Table 2 . Among the 17 patients who underwent monotherapy, 13 (18%) were treated with S, two (3%) with CT, and two (3%) with RT. A total of 55 patients underwent multimodality therapy, including 13 (18%) patients who received CT+RT, 29 (40%) who received S+CT, one (1%) who received S+RT, and 12 (17%) who received S+CT+RT.
Overall survival
All patients were followed until death or December 2013. The median follow-up time was 15.0 (range 3-108) months. For the whole cohort, the median OS was 15.0 months; the 1-year, 2-year, and 3-year OS rates were 56%, 39%, and 27%, respectively ( Figure 1A ). Compared with patients without CT, patients with CT had significantly improved median OS (10.0 months vs 22.8 months) (P=0.03) ( Figure 1B ).
Patients who received multimodality therapy (eg, RT+CT, S+CT, S+RT, or S+RT+CT) had significantly improved OS compared with those who received monotherapy with any technique (15.5 months vs 9.3 months) (P=0.02) ( Figure 1C ). The survival time showed a slight trend towards superiority of S+CT+RT over CT+RT or S+CT, although these differences were not statistically significant because of the small sample (P=0.73) ( Figure 1D ). The aJcc (6th edition) was used for staging. *Platinum-based cT regimens included cisplatin, carboplatin, or oxaliplatin. Abbreviations: aJcc, american Joint committee on cancer; c, clinical; ce, carboplatin + etoposide; cT, chemotherapy; eP, etoposide + cisplatin; iP, irinotecan + cisplatin; PF, cisplatin + 5-fluorouracil; RT, radiotherapy; S, surgery; TNM, tumor/ nodes/metastasis. 
Tumor response and patterns of failure
Prognostic factors
Patient clinical characteristics were evaluated to determine their prognostic value in terms of OS. UVA indicated that sex, age, tumor size, tumor/nodes/metastasis (TNM) classification stage, types of histological components, number of histological components, and CT type were not associated with OS (Table 2) . UVA and MVA revealed that tumor location (upper third of the esophagus) and type of treatment (ie, monotherapy) were associated with worse OS (Tables 3 and 4) .
adverse events
Of all patients, only five (5/72 [7%]) patients had a reported adverse event secondary to treatment. All toxicities were minor (Radiation Therapy Oncology Group [RTOG] grade 2) and included esophagitis, leukopenia, anemia, thrombocytopenia, and bone marrow suppression. And these toxicities were resolved with routine treatment.
Discussion
LS-C-SCEC is a rare subtype of SCEC. The optimal treatment strategy for LS-C-SCEC is controversial. Previous studies have suggested that pure LS-SCEC and LS-C-SCEC The aJcc (6th edition) was used for staging. ‡ The other combined components included sarcomatoid, rosette, and Paget's disease. § Platinum-based cT regimens included cisplatin, carboplatin, or oxaliplatin. *P-value 0.05. Abbreviations: ad, adenocarcinoma; aJcc, american Joint committee on cancer; cT, chemotherapy; ls-c-scec, limited-stage combined small cell esophageal carcinoma; MsT, median survival time; Os, overall survival; sq, squamous cell carcinoma; TNM, tumor/nodes/metastasis.
Survival (probability)
have similar behavior and outcomes, perhaps independent of treatment. 4, 32 However, most of these reports are relatively small retrospective series, and LS-C-SCEC has been included as a subset of patients with LS-SCEC. The current retrospective study demonstrated that LS-C-SCEC should be treated as a unique disease entity. Moreover, LS-C-SCEC patients who received multimodality therapy (which included CT) have significantly improved OS compared with patients receiving monotherapy.
Generally, the size of biopsy and presence of crush artifact, as well as number of study specimens taken by routine biopsy contribute to the underdiagnosis of C-SCEC. 4, 33 In addition, change in histology during the treatment period also makes the diagnosis more challenging, 34 akin to C-SCLC. 35 In this study, the vast majority (55/72 [76%]) of patients were diagnosed by postoperative pathology, which illustrates the importance of histopathological diagnosis. Therefore, it is postulated that the incidence of C-SCEC may be underestimated. In this study, the most frequent histological component was squamous cell carcinoma, in agreement with a previous report. 36 The coexistence of pure SCEC with squamous cell carcinoma or other histologies in the same lesion is supported by the hypothesis that SCEC originates from amine precursor uptake and decarboxylation (APUD) cells or pluripotent stem cells. 37 We believe that the rarity of LS-C-SCEC is the primary reason that there is a lack of consensus regarding its optimal treatment. From a clinical standpoint, our data indicate that LS-C-SCEC has historically been treated similar to non-SCEC, in that S has been an integral treatment approach for LS-C-SCEC (76% of cases) and LS-SCEC. 8 Additionally, we note that patients with pure LS-SCEC have significantly improved OS compared with LS-C-SCEC. 8 The reason for this OS discrepancy is unclear and may be attributed to the fact that small cell carcinoma is typically more radiosensitive than non-SCEC or that the presence of a combined histology is secondary to multiple tumor cell lines.
Compared with LS-C-SCEC patients treated without CT, our results suggest that patients treated with CT have a significantly improved OS. We believe CT is a necessary treatment for both pure SCEC and C-SCEC, akin to patients with SCLC and C-SCLC. In addition, our study demonstrated that multimodality therapy (which includes CT) is associated with improved OS versus monotherapy. The survival time showed a slight trend towards the superiority of S+CT+RT over CT+RT or S+CT, although these differences were not statistically significant because of fewer samples. Previous studies were consistent with our results, although these studies did not strictly focus on C-SCEC compared with other histologies. 10, 11, 38 RT is important in the treatment of small cell carcinoma and non-small cell carcinoma of other disease sites. In this study, a total of 28 patients (28/72 [39%]) received RT, either alone or in combination with S or CT. The indications and contraindications for RT (particularly as trimodality therapy with S and CT) in LS-C-SCEC should be evaluated in future prospective works.
Differences between pure SCEC and C-SCEC in terms of disease biology and pattern of metastatic spread constitute the subject of ongoing debate, and it is hypothesized that the C-SCEC has diverse biological characteristics that may influence tumor aggressiveness and treatment sensitivity. Our previous study demonstrated that the CRs were more 
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Multimodality therapy is recommended for ls-c-scec ). CT appears to be an important treatment modality for both pure SCEC and C-SCEC, as evidenced by rates of CR and OS.
Interestingly, there was a significant difference in the pattern of failure (ie, LRR and DM) between pure patients with LS-SCEC (LRR and DM [76%]) and LS-C-SCEC (LRR and DM [35%]). The incidence of brain metastasis appears to be low in either disease; thus, prophylactic brain irradiation for LS-C-SCEC appears unnecessary.
Previous works have shown that the adverse prognostic factors for SCEC are advanced stage of the disease, tumor location, patient's performance status, and treatment type. 2, 5, 9, [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] In the present study, UVA and MVA identified two independent negative prognostic factors of LS-C-SCEC: tumor location (upper third of the esophagus) and type of treatment (monotherapy, which was typically, S). Additionally, although previous reports have identified the number of histological components to be predictive of outcome in C-SCLC, 12, 13, 39 the present study did not identify histology (either count or subtype) as a predictor of outcome for LS-C-SCEC.
This study has potential weaknesses. First, it is retrospective and based largely on records kept by many institutions, which may have been heterogeneous in their diagnosis and management of patients. Second, the sample size of the present study may not have been optimal; however, LS-C-SCEC is a rare and likely underdiagnosed disease of patients, particularly during the past few decades when the patients were treated. Third, CT, RT, and S have differed widely and have evolved. Finally, some patient data were missing, and with a relatively small number of patients overall, we are unable to discuss the benefit of certain treatments (eg, concurrent vs sequential CT, or salvage therapy).
In conclusion, this study indicates that LS-C-SCEC is a unique disease that should be diagnosed and managed as an entity separate from LS-SCEC. Compared with monotherapy, multimodality therapy (which includes CT) is associated with improved OS for patients with LS-C-SCEC. We recommend that S+CT+RT, S+CT, or CT+RT should be considered as possible treatment approaches for LS-C-SCEC patients.
